Toby M. Maher

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Interstitial Lung Disease in Systemic Sclerosis

Nicole Goh, Sujal R. Desai, Srihari Veeraraghavan et al. · American Journal of Respiratory and Critical Care Medicine · 2008 · 1.2K citations

Medicine, Clinical Sciences, Internal Medicine +17

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 630 citations

Medicine, Clinical Sciences, Pharmacotherapy +6

The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis

Philip L. Molyneaux, Michael J. Cox, Saffron A.G. Willis‐Owen et al. · American Journal of Respiratory and Critical Care Medicine · 2014 · 559 citations

Life Sciences, Genetics, Microbiology +17

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12